Related by context. All words. (Click for frequent words.) 70 carotid endarterectomy CEA 69 periprocedural 67 reinfarction 67 β blockers 67 perioperatively 67 perioperative mortality 67 postprocedure 67 antithrombotic therapy 67 coronary revascularization 66 tirofiban 66 ARCOXIA 66 revascularizations 66 cerebrovascular events 66 postintervention 66 CYPHER R Sirolimus eluting 66 ATACAND 66 NATRECOR ® 66 carotid artery stenting CAS 66 GP IIb IIIa inhibitors 65 elective PCI 65 angiographic outcomes 65 coronary intervention 65 recurrent VTE 65 arterial thromboembolic events 65 LV dysfunction 65 fibrinolytic therapy 65 atherosclerotic renal artery stenosis 65 binary restenosis 65 carotid revascularization 65 ipsilateral stroke 65 ICD implantation 65 dual antiplatelet therapy 65 cilostazol 65 drug eluting stent implantation 65 UA NSTEMI 65 paclitaxel eluting stents 65 sirolimus eluting stents 64 thromboembolic events 64 anticoagulant therapy 64 postoperative mortality 64 Events MACE 64 carotid artery stenting 64 beta blocker therapy 64 Stent thrombosis 64 eptifibatide 64 thromboembolism 64 stent implantation 64 hepatectomy 64 adjuvant radiotherapy 64 definite stent thrombosis 64 NATRECOR R 64 revascularisation 64 Carotid Revascularization Endarterectomy vs. 63 patients undergoing CABG 63 MACCE 63 vaginal hysterectomy 63 percutaneous intervention 63 thrombotic complications 63 VTE prophylaxis 63 dalteparin 63 ARIXTRA 63 coronary interventions 63 IIIa inhibitor 63 Kaplan Meier analysis 63 debulking surgery 63 XIENCE V PROMUS Stent 63 aldosterone antagonists 63 revascularization procedures 63 % CI #.#-#.# [008] 63 Unstable Angina 63 thromboembolic complications 63 CABG surgery 63 noninferior 63 antiarrhythmic drug 63 recurrent ischemia 63 Percutaneous Coronary Intervention 63 symptomatic VTE 63 primary percutaneous coronary 63 morphometric vertebral fractures 63 AVANDIA 63 Coronary artery bypass grafting 63 reoperations 63 TURBT 62 coronary artery occlusion 62 Doxil ® 62 symptomatic carotid stenosis 62 rFVIIa 62 concomitant antibiotics 62 thromboprophylaxis 62 nondiabetic patients 62 antiplatelet drugs 62 dual antiplatelet 62 CYPHER ® 62 VT VF 62 Hypotension 62 Postoperative complications 62 repeat revascularization 62 clopidogrel pretreatment 62 antiplatelet medication 62 TAXUS Stent 62 postoperative chemotherapy 62 sirolimus eluting 62 carotid artery stenosis 62 atorvastatin #mg 62 intravesical therapy 62 simvastatin ezetimibe 62 Coronary Artery Bypass Grafting 62 postoperative atrial fibrillation 62 tenecteplase 62 Taxus Stent 62 proximal DVT 62 antiplatelet therapy 62 atherothrombotic events 62 rebleeding 62 glycoprotein IIb IIIa inhibitors 62 postoperative complication 62 symptomatic intracranial 62 thrombotic events 62 acute STEMI 62 postoperative AF 62 glycoprotein IIb IIIa inhibitor 62 stent thromboses 62 antibiotic prophylaxis 62 fibrinolysis 62 PRADAXA 61 atrioventricular block 61 ICD therapy 61 ticlopidine 61 preintervention 61 thrombolytic therapy 61 ACUITY trial 61 defibrillator implant 61 silent ischemia 61 locoregional recurrence 61 Coronary Artery Bypass Graft 61 ENDEAVOR III 61 MIs 61 clopidogrel Plavix 61 STRIDE PD 61 certolizumab 61 eplerenone 61 lipid lowering therapy 61 BENICAR HCT 61 secondary efficacy endpoint 61 DVT prophylaxis 61 revascularization procedure 61 thromboembolic 61 unfractionated heparin UFH 61 thrombus aspiration 61 angiographically 61 ICD implants 61 FOLFOX4 61 surgical revascularization 61 Operative mortality 61 renal biopsy 61 unfractionated heparin 61 nonfatal MI 61 multivessel disease 61 recurrent DVT 61 oral anticoagulant therapy 61 NSTE ACS 61 LVSD 61 events MACE 61 randomized multicenter Phase III 61 ximelagatran 61 CARE HF 61 endarterectomy 61 postdischarge 61 severe exacerbations 61 oral anticoagulation 61 non valvular atrial 61 myocardial infarction MI 61 CYPHER Stent 61 elevated troponin 61 noncardiac surgery 61 NSTEMI 61 abacavir lamivudine 61 carotid stenosis 61 SCD HeFT 61 liver transplant recipients 61 bowel resection 61 CYPHER ® Sirolimus eluting 61 primary patency 61 rt PA 61 perioperative complications 61 inhospital 61 colectomy 61 anastomotic leak 61 fluvastatin 61 total abdominal hysterectomy 61 revascularisation procedures 61 aspirin clopidogrel 61 invasive aspergillosis 61 Abciximab 61 venous thromboembolisms 61 REOPRO 61 percutaneous interventions 60 adenoma recurrence 60 antimicrobial prophylaxis 60 radical nephrectomy 60 hsCRP levels 60 GP IIb IIIa inhibitor 60 ischemic complications 60 fondaparinux 60 recurrent venous thromboembolism 60 pamidronate 60 alfuzosin 60 HbA 1c levels 60 intravenous diuretics 60 resynchronization therapy 60 curative resection 60 carotid stenting 60 MULTAQ 60 carotid intima media 60 FASLODEX 60 VcMP 60 5-fluorouracil/leucovorin 60 ß blockers 60 androgen suppression 60 diameter stenosis 60 ribavirin therapy 60 Venous thromboembolism 60 stable angina 60 sirolimus stent 60 bisphosphonate therapy 60 PCIs 60 p = NS 60 carotid surgery 60 angioplasty stenting 60 Coronary artery bypass graft 60 TAXUS VI 60 radial artery grafts 60 MERLIN TIMI 60 Subgroup analysis 60 parathyroidectomy 60 mg/m2 cohort 60 transcatheter closure 60 angiographic restenosis 60 noninvasive outpatient 60 recurrent ischemic stroke 60 abciximab 60 unstable angina pectoris 60 DAPT 60 conventional angiography 60 postoperative morbidity 60 bivalirudin alone 60 HBeAg seroconversion 60 FDA defined valvulopathy 60 APEX AMI trial 60 liver resection 60 Carotid endarterectomy 60 total thyroidectomy 60 IFN alfa 60 abdominal hysterectomy 60 Helicobacter pylori eradication 60 percutaneous vertebroplasty 60 everolimus eluting stents 60 CYP#D# inhibitor 60 bivalirudin monotherapy 60 relapsed MM 60 phase IIIb 60 deep venous thromboses 60 Patency 60 BARI 2D 60 Acute Myocardial Infarction 60 antiplatelet medications 60 CABG 60 Cypher Stent 60 aldosterone antagonist 60 nonoperative treatment 60 transthoracic 60 neoadjuvant 60 ischemia driven 60 coronary CTA 60 reintervention 60 FluCAM arm 60 zotarolimus eluting stent 60 bolus dose 60 Erythropoietic therapies may 60 underwent CABG 60 R0 resection 60 ARIMIDEX 60 Subgroup analyzes 60 MADIT II 60 heparin induced thrombocytopenia 60 progression TTP 60 myocardial infarctions 60 RE LY 60 IOP lowering 60 cytoreductive surgery 60 MAGE A3 ASCI 60 eculizumab therapy 59 tipranavir r 59 uncoated stent 59 endometrial carcinoma 59 CROSSER 59 clevidipine 59 NAVISTAR R 59 confirmed thrombotic cardiovascular 59 warfarin therapy 59 levosimendan 59 undergoing coronary angiography 59 pelvic lymph node dissection 59 Major Adverse Cardiac 59 ezetimibe simvastatin 59 carotid artery blockage 59 postoperative bleeding 59 hepatic resection 59 OPCAB 59 biochemical recurrence 59 cystoid macular edema 59 thromboembolic disease 59 intracranial stenosis 59 vertebral fracture 59 biochemical relapse 59 pretest probability 59 acute coronary syndromes ACS 59 Postoperative 59 nesiritide 59 noninferiority 59 Elitek 59 FRAGMIN 59 coronary stenting 59 prospectively stratified 59 Stenting Trial CREST 59 achieved ACR# 59 acute myocardial infarctions 59 cerebral microbleeds 59 lipid lowering drugs 59 upper gastrointestinal bleeding 59 anticlotting drugs 59 Phase IIIb clinical 59 LNG IUS 59 antiangiogenic therapy 59 ARB telmisartan 59 concurrent chemoradiation 59 % CI #.#-#.# [003] 59 underwent percutaneous coronary 59 acute myocardial infarction AMI 59 Renal dysfunction 59 prospective nonrandomized 59 antithrombotic therapies 59 Febrile neutropenia 59 prespecified secondary 59 SYNTAX trial 59 NNT = 59 pulmonary artery catheterization 59 QTc 59 cardiovascular hospitalizations 59 parecoxib 59 CR nPR 59 doxorubicin docetaxel 59 postoperative complications 59 subgroup analyzes 59 inotropic therapy 59 p = #.# [003] 59 intravascular ultrasonography 59 PRADAXA #mg 59 oxymorphone ER 59 undergoing CABG 59 colorectal liver metastases 59 ventricular tachyarrhythmia 59 argatroban 59 mesilate 59 noncardiac 59 iodixanol 59 nephron sparing surgery 59 femoral neck fracture 59 methotrexate monotherapy 59 Known hypersensitivity 59 periprocedural MI 59 diagnostic angiography 59 recurrent GBM 59 Sirolimus eluting 59 REALITY Trial 59 coronary stenosis 59 Val HeFT 59 hemorrhagic complications 59 chemoradiation therapy 59 lymphadenectomy 59 transrectal ultrasound guided 59 pexelizumab 59 intima media thickness 59 TAXUS Liberte Long 59 VIIBRYD 59 conjugated equine estrogen 59 ischemic cardiomyopathy 59 stent restenosis 59 CHARM Added 59 metastatic malignant 59 CALGB # [002] 59 valvulopathy 59 GOUT 59 salpingo oophorectomy 59 poor metabolizers 59 advanced adenoma 59 HORIZONS AMI trial 59 severe neutropenia 59 transurethral resection 59 VADT 59 NEVO ™ 59 severe renal impairment 59 detrusor overactivity 59 ischemic cerebrovascular 59 virologic failure 59 undergo percutaneous coronary 59 thienopyridines 59 unstable angina UA 59 dose cohort 59 SLNB 59 Angiographic 59 pancreatic resection 59 rizatriptan 59 TMP SMX 59 irbesartan 58 CUSTOM III 58 BoNTA 58 venous thromboembolic disease 58 mitral valve replacement 58 nonoperative 58 TAXUS Express Stent 58 Embolic Protection Device 58 metoprolol tartrate 58 patients undergoing percutaneous 58 LAGB 58 MitraClip device 58 ruboxistaurin 58 tumor lysis syndrome 58 Acute Coronary Syndromes 58 GPIIb IIIa inhibitors 58 APTIVUS r 58 EBUS FNA 58 nonfatal myocardial infarction 58 stenting procedures 58 PNH patients 58 gastrointestinal perforations 58 CIMZIA TM certolizumab pegol 58 recurrent myocardial infarction 58 COREG 58 thienopyridine 58 adenoma detection 58 valve implantation 58 pegylated interferon alfa 2b 58 stenoses 58 myocardial infarction stroke 58 target vessel revascularization 58 NEVO 58 pharmacokinetic interaction 58 low dose Iluvien 58 bivalirudin 58 carotid artery stent 58 PFO closure 58 RYGB 58 esophagectomy 58 HSCT 58 carotid angioplasty 58 oral rivaroxaban 58 venous thromboembolism 58 pneumonectomy 58 INVEGA ® 58 Thrombolysis 58 WallFlex Biliary RX 58 paroxysmal AF 58 salmeterol fluticasone 58 milrinone 58 oxycodone CR 58 intracoronary 58 mcg QD 58 prior nephrectomy 58 adenotonsillectomy 58 oncologic outcomes 58 Tarceva TM 58 thrombolytic agents 58 EXJADE 58 Afib 58 Kaplan Meier estimates 58 nonvertebral fracture 58 MIRAPEX 58 lumiracoxib 58 Fondaparinux 58 PSADT 58 dose atorvastatin 58 renal artery stenting 58 AGGRASTAT R 58 #.#/#.# mmHg [001] 58 systemic embolism 58 dose statin therapy 58 mycophenolic acid 58 efficacy endpoint 58 ExTRACT TIMI 58 underwent coronary angiography 58 postsurgical 58 perioperative morbidity 58 DEFINITY ® 58 enoxaparin 58 PASI scores 58 STEMI patients 58 neurologic progression 58 DOXIL 58 recurrent glioblastoma multiforme 58 candesartan cilexetil 58 paroxetine Paxil 58 CYPHER ® Stent 58 prospectively defined 58 postoperative radiotherapy 58 Cordis Cypher 58 TAVR 58 RE LY ® 58 thrombocytopenic 58 percutaneous coronary intervention 58 asthma exacerbation 58 drug eluting coronary stents 58 Hazard Ratio = 58 endometrial hyperplasia 58 postoperative infections 58 ULORIC 58 P = .# 58 nonobstructive CAD 58 pericardial effusion 58 meniscectomy 58 metastatic castration resistant 58 renal artery stenosis 58 adenoidectomy 58 idraparinux 58 arteriography 58 HF hospitalization 58 anticoagulation therapy 58 Vascugel ® 58 labetalol 58 LMWH 58 detectable HCV RNA 58 XIENCE V demonstrated 58 echocardiographic parameters 58 composite endpoint 58 Perforomist Inhalation Solution 58 FFR guided 58 achieved CCyR 58 sirolimus eluting stent 58 glycated hemoglobin levels 58 TAXUS Express2 58 receiving prophylactic anticoagulation 58 pain palliation 58 CI #.#-#.# [001] 58 intravenous bisphosphonates 58 conjugated equine estrogens 58 polypectomy 58 cTnI 58 prostate TURP 58 ZOLINZA 58 endoscopic ultrasonography 58 Pegylated Liposomal Doxorubicin 58 nicardipine 58 REMINYL ® 58 autologous SCT 58 thyroidectomy 58 colon resection 58 everolimus eluting stent 58 Angiox ® 58 hip resurfacing arthroplasty 58 pretransplant 58 tapentadol ER 58 RVOT 58 cystectomy 58 fundoplication 58 Drug eluting stent 58 coronary artery bypass grafts 58 nonadherence 58 uridine triacetate 58 HBeAg negative patients 58 renal denervation 58 percutaneous coronary interventions 58 platelet reactivity 57 preoperative chemotherapy 57 IIIa inhibitors 57 dexmedetomidine 57 mild hepatic impairment 57 pioglitazone HCl 57 R# #mg BID 57 virological response 57 glomerular filtration 57 Fully Covered Stent 57 deep venous thrombosis 57 thrombolytics 57 AVERROES 57 Femara letrozole 57 EFFEXOR XR 57 ACCORD Lipid 57 paliperidone ER 57 stent insertion 57 hyperacute 57 graft occlusion 57 interquartile range 57 nadroparin 57 posttransplant 57 estramustine 57 lipid lowering agents 57 teriflunomide 57 receiving VELCADE 57 postmenopausal osteoporotic women 57 hemodynamically significant 57 infusional 57 APEX AMI 57 anticoagulated 57 IABP 57 Xelox 57 upper endoscopy 57 TAXUS Express Atom Stent 57 concomitant AEDs 57 reblockage 57 myocardial necrosis 57 angiographic follow 57 dobutamine 57 pCR 57 bi ventricular pacing 57 PRIMO CABG 57 refractory ischemia 57 valdecoxib 57 placebo controlled clinical 57 retrospective cohort study 57 HBeAg positive patients 57 #.#mg/dL 57 systemic hypotension 57 liposomal amphotericin B 57 underwent resection 57 MYLOTARG 57 pulmonary resection 57 polyp recurrence 57 NMIBC 57 hemodynamic variables 57 lamotrigine 57 severe hypoglycemic 57 divalproex sodium 57 Bare Metal Stent 57 tamoxifen therapy 57 cerivastatin 57 colorectal adenoma 57 PLX STROKE targeting 57 mycophenolate mofetil 57 mm Stent 57 randomized Phase IIb 57 olmesartan 57 GnRH agonist 57 serum aminotransferase levels 57 tumor progression TTP 57 FRAGMIN R 57 complete cytogenetic response 57 CRp 57 CRESTOR #mg 57 pharmacologic stress 57 carotid endarterectomy 57 oral antidiabetic medication 57 undergoing percutaneous coronary 57 lumbar spine BMD 57 recanalization 57 briakinumab 57 carotid stents 57 remission CR 57 subtrochanteric 57 CRT ICD 57 extubation 57 androgen deprivation 57 ICD shocks 57 sunitinib Sutent 57 ablative therapy 57 transurethral 57 epidural steroid injection 57 platelet inhibition 57 median PFS 57 myocardial infarction 57 pioglitazone Actos 57 prospective multicentre 57 venous thromboembolic events 57 visceral metastases 57 undetectable HBV DNA 57 BENICAR 57 KRAS mutations occur 57 randomizing patients 57 TASKi3 57 unresectable HCC 57 Aprotinin 57 radical prostatectomy RP 57 cisplatin vinorelbine 57 octreotide LAR 57 AVAPRO 57 abnormal uterine bleeding 57 nonischemic 57 anagrelide 57 antiarrhythmic drugs 57 variceal bleeding 57 crossclamp 57 prolonged QT interval 57 antiretroviral naïve 57 macrovascular events 57 Vascular Wrap 57 saphenous vein graft 57 TEAEs 57 advanced adenomas 57 oral diclofenac 57 intravitreal injections 57 % CI #.#-#.# [007] 57 posttreatment 57 renoprotective 57 #mg BID [001] 57 TAXUS p value 57 moderately emetogenic 57 coadministration 57 FROVA 57 gadobutrol 57 onset atrial fibrillation 57 Resolute stent 57 bypass graft CABG surgery 57 edoxaban 57 randomized multicenter trial 57 intracerebral haemorrhage 57 zotarolimus 57 cardiopulmonary bypass CPB 57 tumor resection 57 MGd 57 left ventricular dysfunction 57 activated partial thromboplastin 57 oral antiplatelet therapy 57 Targretin capsules 57 CLARITY study 57 concomitant medications 57 LYSTEDA 57 desvenlafaxine succinate 57 oral FTY# 57 nonfatal myocardial infarction MI 57 EURIDIS 57 attain statistical significance 57 intensive statin therapy 57 adrenalectomy 57 restenotic lesions 57 genotypic resistance 57 chemoembolization 57 lamivudine monotherapy 57 contralateral prophylactic mastectomy 57 #mg QD [001] 57 undergoing coronary artery 57 endovascular repair 57 insulin detemir 57 zoledronic acid Zometa 57 HBV infections 57 CCyR 57 adalimumab Humira 57 Cardiopulmonary bypass 57 serum phosphorous 57 radiotherapy RT 57 MIST II 57 ventricular dysfunction 57 catheter occlusion 57 antiplatelet agents 57 LV ejection fraction 57 hypofractionated radiation 57 Target Lesion Revascularization TLR 57 sipuleucel T 57 REVLIMID R 57 pulmonary artery banding 57 gastrectomy 57 duplex ultrasonography 57 CABG surgeries 57 wound dehiscence 57 graft patency 57 pulmonary toxicity 57 rtPA 57 plus prednisone 57 cholecystectomy 57 paclitaxel eluting stent 57 nonvertebral fractures 57 nonrandomized 57 nephrectomy 57 histological subtype 57 lung resections 57 flutamide 56 radical retropubic prostatectomy 56 reoperation 56 myocardial viability 56 plus glycoprotein IIb 56 liver metastasis 56 MEND CABG 56 cardiac resynchronisation therapy 56 Laura Mauri 56 Free Survival PFS 56 stenting 56 Secondary endpoints 56 decompressive surgery 56 angiotensin II receptor blockers 56 LOVENOX R 56 QTc prolongation 56 CHAMPION PCI 56 transcatheter aortic valve implantation 56 COPD exacerbations 56 NSABP B 56 Pemetrexed 56 angiotensin converting enzyme inhibitor 56 biliary tract cancer 56 Ereska 56 postoperative infection 56 lymphocytosis 56 coronary revascularization procedures 56 VaD 56 Guideline Update 56 anticoagulation 56 laparoscopically assisted 56 prophylactic cranial irradiation 56 hepatorenal syndrome 56 coronary arteriography 56 PONV 56 Percutaneous coronary intervention 56 ADHF 56 anthracycline taxane 56 aneurysmal subarachnoid hemorrhage 56 inhospital mortality 56 acute cholecystitis 56 bisoprolol 56 SPIRIT FIRST 56 riociguat 56 bypass grafting 56 aneurysm rupture 56 dose escalation phase 56 sotalol 56 amoxicillin clavulanate 56 glucocorticoid induced osteoporosis 56 intraoperative complications 56 Nesiritide 56 Gheorghiade 56 androgen suppression therapy 56 secondary efficacy endpoints 56 enoxaparin Lovenox 56 INFERGEN 56 ACTEMRA TM 56 oocytes retrieved 56 receiving SIMPONI 56 cardiac tamponade 56 coagulation parameters 56 EBRT 56 Platinol ® 56 Randomized controlled 56 venous thromboembolic 56 pulmonary capillary wedge 56 ribavirin RBV 56 Stenting 56 undergoing radical prostatectomy 56 somatostatin analog 56 bezafibrate 56 mL/min/#.# m 2 56 carotid IMT 56 TAXUS V 56 workhorse lesions 56 CIMZIA ™ 56 Polyp Prevention Trial 56 DEFINITY R 56 SIMPADICO 56 mRCC 56 radioiodine therapy 56 serum creatinine levels 56 multivariate adjustment 56 salmeterol HFA MDI 56 Median PFS 56 symptomatic hyponatremia 56 Ejection Fraction 56 QTc intervals 56 Thalomid ® 56 lung resection 56 substudy 56 infarction NSTEMI 56 PRISTIQ 56 renal insufficiency 56 Acute Coronary Syndrome 56 acute aortic dissection 56 events TEAEs 56 multicenter randomized controlled 56 chlorambucil 56 otamixaban 56 Cypher Sirolimus 56 ACTOS ® 56 myocardial infarctions MIs 56 serum calcium levels 56 fragility fracture 56 non selective NSAIDs 56 Kaplan Meier 56 symptomatic intracerebral hemorrhage 56 systolic hypertension 56 undergone radical prostatectomy 56 intensive lipid lowering 56 TAXUS Liberté stent 56 cinacalcet 56 myocardial revascularization 56 postoperative pulmonary 56 de novo AML 56 REVLIMID ® 56 Postoperatively 56 cytoreductive nephrectomy 56 clinically localized prostate 56 CI #.#-#.# [002] 56 Angiox R 56 BARACLUDE ® 56 occlusive disease 56 plus dexamethasone 56 revascularization 56 pimecrolimus cream 56 pooled comparator 56 Carotid Artery Stenting 56 locoregional 56 VELCADE melphalan 56 VTE prevention 56 neoadjuvant treatment 56 Vorapaxar 56 myocardial infarction ventricular fibrillation 56 multicenter prospective 56 CR CRu 56 GnRH agonists 56 resectable pancreatic cancer 56 defibrillator CRT D 56 dronedarone 56 PREVENT IV 56 mycophenolate mofetil MMF 56 HCV RESPOND 2 56 directed thrombolysis 56 FOLPI 56 icatibant 56 TAXUS Express 56 pulmonary angiography 56 landmark ATHENA 56 statistical significance p 56 bendamustine 56 benazepril 56 SilverHawk Plaque Excision System 56 conventional coronary angiography 56 coronary angiography 56 Endeavor Drug Eluting 56 corrected QT interval 56 polycythemia vera essential thrombocythemia 56 mcg BID 56 FDG PET imaging 56 neointimal hyperplasia 56 incomplete revascularization 56 relapsed ALL 56 SYNTAX 56 coronary revascularisation 56 cardiovascular hospitalization 56 stent binary restenosis 56 β blocker 56 renal scarring 56 thoracoscopic lobectomy 56 candidemia 56 invasive candidiasis 56 sunitinib malate 56 TWYNSTA 56 PSA nadir 56 biologic DMARD 56 lumen diameter 56 neointimal 56 tachyarrhythmia 56 osteoporotic compression fractures 56 residual stenosis 56 Teriflunomide 56 nadolol 56 eluting stent 56 confidence interval #.#-#.# 56 clodronate 56 TAXUS TM 56 prospective multicenter study 56 portal vein thrombosis 56 CRT Ds 56 mCRPC 56 galiximab 56 prednisone prednisolone 56 RE LY trial 56 RELIANT Trial 56 univariate analysis 56 vasopressor 56 FOLFIRI alone 56 PROMUS R 56 noncardiovascular mortality 56 adjuvant radiation 56 Myocardial Infarction TIMI 56 XELOX 56 MEVACOR 56 INTEGRILIN R 56 cryptogenic stroke 56 hemodynamically stable 56 Ventavis ® 56 antithrombotic 56 prospective observational studies 56 Carvedilol 56 Dabigatran 56 sustained virological response 56 Contraindications 56 clinicopathological features 56 HbA1C levels 56 post operatively 56 CDI recurrence 56 mg BID dose 56 postoperative hemorrhage 56 systemic corticosteroids 56 Skin sterol 56 CANCIDAS 56 dose clopidogrel